{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:25Z","timestamp":1792616425177,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007027","name":"Leon Levy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11060-021-03827-2","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T10:03:31Z","timestamp":1629281011000},"page":"301-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes"],"prefix":"10.1007","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0381-1995","authenticated-orcid":false,"given":"Evan D.","family":"Bander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L. A.","family":"Garton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron W.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-1681","authenticated-orcid":false,"given":"Nelson S.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"issue":"5","key":"3827_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5(5):443\u2013452. https:\/\/doi.org\/10.1016\/S1474-4422(06)70443-4","journal-title":"Lancet Neurol"},{"issue":"3","key":"3827_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"SD Ferguson","year":"2019","unstructured":"Ferguson SD, Bindal S, Bassett RL et al (2019) Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142(3):499\u2013509. https:\/\/doi.org\/10.1007\/s11060-019-03121-2","journal-title":"J Neurooncol"},{"issue":"6","key":"3827_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1215\/15228517-2008-062","volume":"10","author":"L Harstad","year":"2008","unstructured":"Harstad L, Hess KR, Groves MD (2008) Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10(6):1010\u20131018. https:\/\/doi.org\/10.1215\/15228517-2008-062","journal-title":"Neuro Oncol"},{"issue":"2","key":"3827_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","volume":"8","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Lee J-I, Nam D-H et al (2013) Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 8(2):185\u2013191. https:\/\/doi.org\/10.1097\/JTO.0b013e3182773f21","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3827_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/cncr.24041","volume":"115","author":"J Bruna","year":"2009","unstructured":"Bruna J, Gonz\u00e1lez L, Mir\u00f3 J et al (2009) Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115(2):381\u2013389. https:\/\/doi.org\/10.1002\/cncr.24041","journal-title":"Cancer"},{"issue":"2","key":"3827_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","volume":"223","author":"U Herrlinger","year":"2004","unstructured":"Herrlinger U, F\u00f6rschler H, K\u00fcker W et al (2004) Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223(2):167\u2013178. https:\/\/doi.org\/10.1016\/j.jns.2004.05.008","journal-title":"J Neurol Sci"},{"issue":"4","key":"3827_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","volume":"49","author":"WR Wasserstrom","year":"1982","unstructured":"Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759\u2013772","journal-title":"Cancer"},{"issue":"18","key":"3827_CR8","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","volume":"40","author":"W Boogerd","year":"2004","unstructured":"Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40(18):2726\u20132733. https:\/\/doi.org\/10.1016\/j.ejca.2004.08.012","journal-title":"Eur J Cancer"},{"issue":"1","key":"3827_CR9","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","volume":"19","author":"H Cheng","year":"2018","unstructured":"Cheng H, Perez-Soler R (2018) Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 19(1):e43\u2013e55. https:\/\/doi.org\/10.1016\/S1470-2045(17)30689-7","journal-title":"Lancet Oncol"},{"key":"3827_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","volume":"135","author":"MA Franzoi","year":"2019","unstructured":"Franzoi MA, Hortobagyi GN (2019) Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol 135:85\u201394. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.020","journal-title":"Crit Rev Oncol Hematol"},{"key":"3827_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33459","author":"ED Bander","year":"2021","unstructured":"Bander ED, Yuan M, Carnevale JA et al (2021) Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer. https:\/\/doi.org\/10.1002\/cncr.33459","journal-title":"Cancer"},{"issue":"9","key":"3827_CR12","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1","volume":"82","author":"F Bokstein","year":"1998","unstructured":"Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82(9):1756\u20131763","journal-title":"Cancer"},{"issue":"2","key":"3827_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1081\/CNV-50458","volume":"23","author":"LM DeAngelis","year":"2005","unstructured":"DeAngelis LM, Boutros D (2005) Leptomeningeal metastasis. Cancer Invest 23(2):145\u2013154","journal-title":"Cancer Invest"},{"issue":"2","key":"3827_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208\u2013215. https:\/\/doi.org\/10.1215\/15228517-2007-059","journal-title":"Neuro Oncol"},{"issue":"11","key":"3827_CR15","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A Randomized Controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394\u20133402","journal-title":"Clin Cancer Res"},{"key":"3827_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01224","author":"SM Buszek","year":"2019","unstructured":"Buszek SM, Chung C (2019) Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.01224","journal-title":"Front Oncol"},{"issue":"9","key":"3827_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1212\/01.WNL.0000160396.69050.DC","volume":"64","author":"AMP Omuro","year":"2005","unstructured":"Omuro AMP, Lallana EC, Bilsky MH, DeAngelis LM (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64(9):1625\u20131627. https:\/\/doi.org\/10.1212\/01.WNL.0000160396.69050.DC","journal-title":"Neurology"},{"key":"3827_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1595-7","author":"HS Kim","year":"2019","unstructured":"Kim HS, Park JB, Gwak H-S, Kwon J-W, Shin S-H, Yoo H (2019) Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis. World J Surg Oncol. https:\/\/doi.org\/10.1186\/s12957-019-1595-7","journal-title":"World J Surg Oncol"},{"issue":"6","key":"3827_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/mco.2015.627","volume":"3","author":"F Nigim","year":"2015","unstructured":"Nigim F, Critchlow JF, Kasper EM (2015) Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: an analysis of 59 cases. Mol Clin Oncol 3(6):1381\u20131386. https:\/\/doi.org\/10.3892\/mco.2015.627","journal-title":"Mol Clin Oncol"},{"key":"3827_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210074","author":"K Mitsuya","year":"2019","unstructured":"Mitsuya K, Nakasu Y, Hayashi N et al (2019) Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: a single-center retrospective study. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0210074","journal-title":"PLoS ONE"},{"key":"3827_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clineuro.2018.03.008","volume":"168","author":"Y Murakami","year":"2018","unstructured":"Murakami Y, Ichikawa M, Bakhit M et al (2018) Palliative shunt surgery for patients with leptomeningeal metastasis. Clin Neurol Neurosurg 168:175\u2013178. https:\/\/doi.org\/10.1016\/j.clineuro.2018.03.008","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"3827_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11060-018-2949-7","volume":"140","author":"N Lamba","year":"2018","unstructured":"Lamba N, Fick T, Nandoe Tewarie R, Broekman ML (2018) Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making. J Neurooncol 140(1):5\u201313. https:\/\/doi.org\/10.1007\/s11060-018-2949-7","journal-title":"J Neurooncol"},{"issue":"23","key":"3827_CR23","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1002\/cncr.32454","volume":"125","author":"G Schvartsman","year":"2019","unstructured":"Schvartsman G, Ma J, Bassett RL et al (2019) Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125(23):4193\u20134202. https:\/\/doi.org\/10.1002\/cncr.32454","journal-title":"Cancer"},{"issue":"9","key":"3827_CR24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","volume":"6","author":"JB Iorgulescu","year":"2018","unstructured":"Iorgulescu JB, Harary M, Zogg CK et al (2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res 6(9):1039\u20131045. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0067","journal-title":"Cancer Immunol Res"},{"issue":"32","key":"3827_CR25","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. JCO 38(32):3773\u20133784. https:\/\/doi.org\/10.1200\/JCO.20.01255","journal-title":"JCO"},{"issue":"2","key":"3827_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-010-0512-2","volume":"104","author":"SH Lee","year":"2011","unstructured":"Lee SH, Kong DS, Seol HJ, Nam D-H, Lee J-I (2011) Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 104(2):545\u2013551. https:\/\/doi.org\/10.1007\/s11060-010-0512-2","journal-title":"J Neurooncol"},{"key":"3827_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/2152-7806.100185","volume":"3","author":"DD Gonda","year":"2012","unstructured":"Gonda DD, Kim TE, Warnke PC, Kasper EM, Carter BS, Chen CC (2012) Ventriculoperitoneal shunting versus endoscopic third ventriculostomy in the treatment of patients with hydrocephalus related to metastasis. Surg Neurol Int 3:97. https:\/\/doi.org\/10.4103\/2152-7806.100185","journal-title":"Surg Neurol Int"},{"issue":"4","key":"3827_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3171\/2018.5.JNS1875","volume":"131","author":"E Giordan","year":"2018","unstructured":"Giordan E, Palandri G, Lanzino G, Murad MH, Elder BD (2018) Outcomes and complications of different surgical treatments for idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis. J Neurosurg 131(4):1024\u20131036. https:\/\/doi.org\/10.3171\/2018.5.JNS1875","journal-title":"J Neurosurg"},{"issue":"6","key":"3827_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3171\/jns.1991.74.6.0872","volume":"74","author":"MS Berger","year":"1991","unstructured":"Berger MS, Baumeister B, Geyer JR, Milstein J, Kanev PM, LeRoux PD (1991) The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 74(6):872\u2013877. https:\/\/doi.org\/10.3171\/jns.1991.74.6.0872","journal-title":"J Neurosurg"},{"issue":"5","key":"3827_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/1971400915609348","volume":"28","author":"A Narayan","year":"2015","unstructured":"Narayan A, Jallo G, Huisman TA (2015) Extracranial, peritoneal seeding of primary malignant brain tumors through ventriculo-peritoneal shunts in children: case report and review of the literature. Neuroradiol J 28(5):536\u2013539. https:\/\/doi.org\/10.1177\/1971400915609348","journal-title":"Neuroradiol J"},{"key":"3827_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/2152-7806.82083","volume":"2","author":"CC Chen","year":"2011","unstructured":"Chen CC, Kasper E, Warnke P (2011) Palliative stereotactic-endoscopic third ventriculostomy for the treatment of obstructive hydrocephalus from cerebral metastasis. Surg Neurol Int 2:76. https:\/\/doi.org\/10.4103\/2152-7806.82083","journal-title":"Surg Neurol Int"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03827-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03827-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03827-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:49:20Z","timestamp":1632998960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03827-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03827-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of research execution and publication, all authors are affiliated with Memorial Sloan Kettering Cancer Center. The authors of this research deny any conflict of interest regarding this study and make the following disclosures: NSM: consulting fees for advisory board participation from AstraZeneca and trial support from GT Medical Technologies (to institution) unrelated to the current work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the IRB at Memorial Sloan Kettering Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}